Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
Acute promyelocytic leukemia (APL) is characterized by a t(15;17) translocation that yields a PML/RARA fusion protein. Expression of PML/RARA, a potent transcriptional repressor, induces APL in mice. Both retinoic acid (RA) and arsenic trioxide directly target PML/RARA-mediated transcriptional repression and protein stability, inducing rapid differentiation of the promyelocytes and clinical remission in most APL patients. RA also triggers growth arrest and progressive clearance of leukemia initiating cells (LIC), both ex vivo and in vivo. Suboptimal RA concentrations or expression of the PLZF/RARA variant allows complete RA-induced differentiation, but neither LIC clearance nor disease remission. Thus, RA-induced differentiation and LIC clearance may be uncoupled. The RA/arsenic trioxide association, which dramatically synergizes for PML/RARA degradation but not for differentiation, rapidly clears LIC in a proteasome-dependent manner, resulting in APL eradication in murine models and patients. Collectively, these results demonstrate that LIC clearance, which mirrors PML/RARA degradation, is the primary basis for APL cure by the RA/arsenic trioxide association, rather than differentiation. Oncogene degradation could be a generally applicable therapeutic strategy to clear LICs in several types of tumors.
Nasr
Rihab
R
Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
de Thé
Hugues
H
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000077237:Arsenic Trioxide; D001152:Arsenicals / Q000627:therapeutic use*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D042381:Granulocyte Precursor Cells / Q000187:drug effects* / Q000473:pathology; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D051379:Mice; D015514:Oncogene Proteins, Fusion / Q000235:genetics* / Q000378:metabolism; D009857:Oncogenes / Q000187:drug effects; D010087:Oxides / Q000627:therapeutic use*; D014212:Tretinoin / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D001152:Arsenicals; D015514:Oncogene Proteins, Fusion; D010087:Oxides; C093476:promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein; D014212:Tretinoin; D000077237:Arsenic Trioxide
Oncogene. 2001 Oct 29;20(49):7257-65
11704854
Blood. 2001 Jan 1;97(1):264-9
11133770
Blood. 1998 Oct 1;92(7):2244-51
9746761
J Exp Med. 2002 Nov 18;196(10):1373-80
12438428
Oncogene. 2002 May 13;21(21):3445-58
12032781
Nat Cell Biol. 2008 May;10(5):547-55
18408733
EMBO J. 1994 Mar 1;13(5):1073-83
8131741
EMBO J. 2009 Jan 7;28(1):34-47
19078967
Proc Natl Acad Sci U S A. 1997 Apr 15;94(8):3978-83
9108090
Cancer Cell. 2007 Jul;12(1):23-35
17613434
Cell. 1994 Jan 28;76(2):333-43
8293467
Nat Med. 2008 Dec;14(12):1333-42
19029980
N Engl J Med. 2009 Feb 26;360(9):928-30
19246367
J Natl Cancer Inst. 1998 Jan 21;90(2):124-33
9450572
Proc Natl Acad Sci U S A. 2004 Apr 13;101(15):5328-35
15044693
N Engl J Med. 1993 Jul 15;329(3):177-89
8515790
Cell. 1997 Jul 11;90(1):97-107
9230306
Mol Cell. 2000 May;5(5):811-20
10882117
J Exp Med. 2001 Jun 18;193(12):1361-71
11413191
Cancer Cell. 2007 Jun;11(6):513-25
17560333
Blood. 2009 Dec 24;114(27):5415-25
19797526
Blood. 1999 Jul 15;94(2):793-802
10397747
Cancer Cell. 2009 Jan 6;15(1):7-8
19111876
Nat Rev Mol Cell Biol. 2007 Dec;8(12):1006-16
17928811
Oncogene. 2001 Oct 29;20(49):7140-5
11704842
Blood. 2009 Dec 24;114(27):5499-511
19855079
Oncogene. 1996 Jun 6;12(11):2451-9
8649787
Cancer Cell. 2005 Feb;7(2):143-53
15710327
Biochim Biophys Acta. 1997 Dec 9;1333(3):M53-61
9426202
Blood. 1995 Feb 15;85(4):1083-94
7849296
Trends Cell Biol. 2005 Sep;15(9):494-501
16084092
Leukemia. 1998 Nov;12(11):1829-33
9823961
Blood. 1988 Aug;72(2):567-72
3165295
Blood. 2008 Mar 1;111(5):2505-15
18299451
Haematologica. 2007 Mar;92(3):323-31
17339181
Blood. 2002 Feb 1;99(3):1014-22
11807007
Nature. 1998 Feb 19;391(6669):815-8
9486655
Cancer Res. 2005 Oct 1;65(19):8754-65
16204045
EMBO J. 1993 Mar;12(3):1161-7
8384553
J Exp Med. 2004 Apr 19;199(8):1163-74
15096541
Blood. 1999 May 15;93(10):3167-215
10233871
Leuk Lymphoma. 2006 Jun;47(6):1062-8
16840198
Nat Rev Cancer. 2005 Oct;5(10):821-7
16175176
J Exp Med. 1999 Apr 5;189(7):1043-52
10190895
Blood. 2006 Apr 1;107(7):2627-32
16352810
Blood. 2001 Jan 1;97(1):73-80
11133744
Blood. 1997 May 1;89(9):3345-53
9129041
Nature. 2008 Jun 19;453(7198):1072-8
18469801
Proc Natl Acad Sci U S A. 2005 Nov 15;102(46):16608-13
16275922
Proc Natl Acad Sci U S A. 2006 Jun 20;103(25):9548-53
16769902
Blood. 2006 May 1;107(9):3469-73
16373661
Genes Dev. 2009 May 15;23(10):1195-206
19451220
Nat Genet. 1998 Feb;18(2):126-35
9462740
Blood. 1995 May 15;85(10):2643-53
7742522
Leukemia. 2009 Aug;23(8):1462-71
19322209
Cancer Cell. 2010 Feb 17;17(2):173-85
20159609
Nature. 1998 Feb 19;391(6669):811-4
9486654
Cancer Cell. 2007 Jul;12(1):36-51
17613435
Cancer Cell. 2006 Feb;9(2):73-4
16473273
Nat Cell Biol. 2008 May;10(5):538-46
18408734
Clin Cancer Res. 2009 Oct 15;15(20):6321-6
19808868
Proc Natl Acad Sci U S A. 1999 Dec 21;96(26):14807-12
10611294
Ann Oncol. 2006 Jan;17(1):131-4
16227315
Blood. 1996 Aug 1;88(3):1052-61
8704214
Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3342-7
19225113
Proc Natl Acad Sci U S A. 2000 Aug 29;97(18):10173-8
10954752
Haematologica. 2006 Dec;91(12 Suppl):ECR58
17194664
Mol Cell. 2000 May;5(5):821-30
10882118